BACK

Hepatic and Biliary Tract > HCC

Clinical trial information


Select trial for more information

Area under investigation,BTCs,HCC=true,uHCC

ARTEMIDE-Biliary01 trial overview

Tumor

BTCs after resection with curative intent

Trial Identifier

NCT06109779

Phase

III

Stage

Early

Regimen

Rilvegostomig + investigator's choice of chemotherapy; placebo + investigator's choice of chemotherapy

Visit ct.gov
Go

ARTEMIDE-Biliary02 trial overview

Tumor

Advanced BTC including intra-hepatic or extra-hepatic CCA and GBC

Trial Identifier

NCT07221253

Phase

III

Regimen

Rilvegostomig + gemcitabine/cisplatin; durvalumab + gemcitabine/cisplatin

Visit ct.gov
Go

ARTEMIDE-HCC01 trial overview

Tumor

Locally advanced or metastatic and/or unresectable HCC

Trial Identifier

NCT06921785

Phase

III

Regimen

Tremelimumab IV + rilvegostomig IV + bevacizumab IV; rilvegostomig IV + bevacizumab IV; atezolizumab IV + bevacizumab IV

Visit ct.gov
Go

ATHENA trial overview

Tumor

GPC3+ Advanced/Recurrent HCC

Trial Identifier

NCT06084884

Phase

II-III

Stage

BCLC Stage B (not amenable to locoregional therapy) or BCLC Stage C prior to apheresis

Regimen

AZD7003

Visit ct.gov
Go

BLUESTAR trial overview

Tumor

Advanced solid tumors (breast cancer, BTCs, ovarian cancer, endometrial cancer, squamous NSCLC)

Trial Identifier

NCT05123482

Phase

I/IIa

Regimen

Puxitatug samrotecan monotherapy; puxitatug samrotecan + rilvegostomig; puxitatug samrotecan + rilvegostomig + palacaparib

Visit ct.gov
Go

CLARITY-PanTumor01 trial overview

Tumor

Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)

Trial Identifier

NCT06219941

Phase

II

Regimen

Sonesitatug vedotin; sonesitatug vedotin + chemotherapy

Visit ct.gov
Go

DESTINY-BTC01 trial overview

Tumor

Advanced HER2-expressing BTCs, 1L

Trial Identifier

NCT06467357

Phase

III

Regimen

T-DXd  + rilvegostomig; T-DXd; gemcitabine + cisplatin + durvalumab

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

GEMINI-HPB trial overview

Tumor

Advanced hepatobiliary cancers (HCC, BTCs)

Trial Identifier

NCT05775159

Phase

II

Stage

Unresectable, advanced or metastatic

Regimen

In HCC - volrustomig monotherapy; volrustomig + bevacizumab or lenvatinib or rilvegostomig + bevacizumab; rilvegostomig + bevacizumab. In BTCs - volrustomig + gemcitabine and cisplatin; rilvegostomig + gemcitabine and cisplatin

Visit ct.gov
Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

STARLIGHT trial overview

Tumor

GPC3-positive advanced/recurrent HCC

Trial Identifier

NCT06590246

Phase

I/II

Regimen

Part A1 (dose escalation): AZD7003; Part A2 (dose expansion): AZD7003

Visit ct.gov
Go

TROPION-PanTumor03 trial overview

Tumor

Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)

Trial Identifier

NCT05489211

Phase

II

Regimen

Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.